Short-term treatment with hepatoselective NO donor V-PYRRO/NO improves blood flow in hepatic microcirculation in liver steatosis in mice (original) (raw)

References

  1. Mantena S.K., Vaughn DP, Andringa KK, Eccleston HB, King AL, Abrams Ga, et al. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem J 2009;417:183–93.
    Article CAS Google Scholar
  2. Ijaz S, Yang W, Winslet MC, Seifalian AM. Impairment of hepatic microcirculation in fatty liver. Microcirculation 2003;10:447–56.
    Article CAS Google Scholar
  3. Francque S, Laleman W, Verbeke L, Van Steenkiste C, Casteleyn C, Kwanten W, et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Lab Investig 2012;92:1428–39.
    Article CAS Google Scholar
  4. Hirsova P, Ibrahim SH, Krishnan A, Verma VK, Bronk SF, Werneburg NW, et al. Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes. Gastroenterology 2016;150:956–67.
    Article CAS Google Scholar
  5. Sarphie TG, D’Souza NB, Deaciuc IV. Kupffer cell inactivation prevents lipopolysaccharide-induced structural changes in the rat liver sinusoid: an electron-microscopic study. Hepatology 1996;23:788–96.
    Article CAS Google Scholar
  6. Maslak E, Gregorius A, Chlopicki S. Liver sinusoidal endothelial cells (LSECs) function and NAFLD; NO-based therapy targeted to the liver. Pharmacol Rep 2015;67:689–94.
    Article CAS Google Scholar
  7. Oteiza A, Li R, McCuskey RS, Smedsrød B, Sørensen KK. Effects of oxidized low-density lipoproteins on the hepatic microvasculature. Am J Physiol Gastrointest Liver Physiol 2011;301:G684–93.
    Article CAS Google Scholar
  8. Walenbergh SMA, Koek GH, Bieghs V, Shiri-Sverdlov R. Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J Hepatol 2013;58:801–10.
    Article CAS Google Scholar
  9. Zhang Q, Liu J, Liu J, Huang W, Tian L, Quan J, et al. OxLDL induces injury and defenestration of human liver sinusoidal endothelial cells via LOX1. J Mol Endocrinol 2014;53:281–93.
    Article CAS Google Scholar
  10. Li R, Oteiza A, Sørensen KK, McCourt P, Olsen R, Smedsrød B, et al. Role of liver sinusoidal endothelial cells and stabilins in elimination of oxidized low-density lipoproteins. Am J Physiol Gastrointest Liver Physiol 2011;300:G71–81.
    Article CAS Google Scholar
  11. Simon-Santamaria J, Malovic I, Warren A, Oteiza A, Le Couteur D, Smedsrod B, et al. Age-related changes in scavenger receptor-mediated endocytosis in rat liver sinusoidal endothelial cells. Journals Gerontol Ser a-Biological Sci Med Sci 2010;65:951–60.
    Article Google Scholar
  12. Le Couteur DG, Fraser R, Cogger VC, McLean AJ. Hepatic pseudocapillarisation and atherosclerosis in ageing. Lancet 2002;359:1612–5.
    Article Google Scholar
  13. Kim C-H, Park J-Y, Lee K-U, Kim J-H, Kim H-K. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med 2008;25:476–81.
    Article CAS Google Scholar
  14. Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010;25:352–6.
    Article CAS Google Scholar
  15. Kasturiratne A, Weerasinghe S, Dassanayake AS, Rajindrajith S, de Silva AP, Kato N, et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol 2012;28:1–23.
    Google Scholar
  16. Martinez I, Sveinbjornsson B, Vidal-Vanaclocha F, Asumendi A, Smedsrod B. Differential cytokine-mediated modulation of endocytosis in rat liver endothelial cells. Biochem Biophys Res Commun 1995;212:235–41.
    Article CAS Google Scholar
  17. Martinez I, Sveinbjornsson B, Smedsrod B. Nitric oxide down-regulates endocytosis in rat liver endothelial cells. Biochem Biophys Res Commun 1996;222:688–93.
    Article CAS Google Scholar
  18. Bari K, Garcia-Tsao G. Treatment of portal hypertension. World J Gastroenterol 2012;18:1166–75.
    Article CAS Google Scholar
  19. Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology 2007;132:709–19.
    Article CAS Google Scholar
  20. Fiorucci S, Antonelli E, Brancaleone V, Sanpaolo L, Orlandi S, Distrutti E, et al. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J Hepatol 2003;39:932–9.
    Article CAS Google Scholar
  21. Garcı’a-Villafranca J, Guillén A, Castro J. Involvement of nitric oxide/cyclic GMP signaling pathway in the regulation of fatty acid metabolism in rat hepatocytes. Biochem Pharmacol 2003;65:807–12.
    Article Google Scholar
  22. Kurowska EM, Carroll KK. Hypocholesterolemic properties of nitric oxide: in vivo and in vitro studies using nitric oxide donors. Biochim Biophys Acta 1998;1392:41–50.
    Article CAS Google Scholar
  23. Piatti P, Monti LD, Valsecchi G, Magni F, Setola E, Marchesi F, et al. Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care 2001;24:875–80.
    Article CAS Google Scholar
  24. Kus K, Walczak M, Maslak E, Zakrzewska A, Gonciarz-Dytman A, Zabielski P, et al. Hepatoselective NO-donors, V-PYRRO/NO and V-PROLI/NO in Nonalcoholic Fatty Liver Disease: a comparison of anti-steatotic effects with the biotransformation and pharmacokinetics. Drug Metab Dispos 2015;43(July (7)):1028–36.
    Article CAS Google Scholar
  25. Kim YM, Kim TH, Chung HT, Talanian RV, Yin XM, Billiar TR. Nitric oxide prevents tumor necrosis factor alpha-induced rat hepatocyte apoptosis by the interruption of mitochondrial apoptotic signaling through S-nitrosylation of caspase-8. Hepatology 2000;32:770–8.
    Article CAS Google Scholar
  26. Liu J, Li C, Waalkes MP, Clark J, Myers P, Saavedra JE, et al. The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced hepatotoxicity in mice. Hepatology 2003;37:324–33.
    Article CAS Google Scholar
  27. Ricciardi R, Foley DP, Quarfordt SH, Saavedra JE, Keefer LK, Wheeler SM, et al. V-PYRRO/NO: an hepato-selective nitric oxide donor improves porcine liver hemodynamics and function after ischemia reperfusion. Transplantation 2001;71:193–8.
    Article CAS Google Scholar
  28. Moal F, Veal N, Vuillemin E, Barrière E, Wang J, Fizanne L, et al. Hemodynamic and anti fi brotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats. World J Gastroenterol 2006;12:6639–45.
    Article CAS Google Scholar
  29. Edwards C, Feng H-Q, Reynolds C, Mao L, Rockey DC. Effect of the nitric oxide donor V-PYRRO/NO on portal pressure and sinusoidal dynamics in normal and cirrhotic mice. Am J Physiol Gastrointest Liver Physiol 2008;294:G1311–7.
    Article CAS Google Scholar
  30. Maslak E, Zabielski P, Kochan K, Kus K, Jasztal A, Sitek B, et al. The liver-selective NO donor, V-PYRRO/NO, protects against liver steatosis and improves postprandial glucose tolerance in mice fed high fat diet. Biochem Pharmacol 2015;93:389–400.
    Article CAS Google Scholar
  31. Venn BJ, Green TJ. Glycemic index and glycemic load: measurement issues and their effect on diet-disease relationships. Eur J Clin Nutr 2007;61:S122–31.
    Article CAS Google Scholar
  32. Nozaki Y, Fujita K, Wada K, Yoneda M, Shinohara Y, Imajo K, et al. Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution. BMC Gastroenterol 2015;15:177.
    Article Google Scholar
  33. DeLeve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology 2008;48:920–30.
    Article CAS Google Scholar
  34. Moal F, Veal N, Vuillemin E, Barrière E, Wang J, Fizanne L, et al. Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRO/NO in bile duct ligated rats. World J Gastroenterol 2006;12:6639–45.
    Article CAS Google Scholar
  35. Pasarín M, Abraldes JG, Rodríguez-Vilarrupla A, La Mura V, García-Pagán JC, Bosch J. Insulin resistance and liver microcirculation in a rat model of early NAFLD. J Hepatol 2011;55:1095–102.
    Article Google Scholar
  36. Miyao M, Kotani H, Ishida T, Kawai C, Manabe S, Abiru H, et al. Pivotal role of liver sinusoidal endothelial cells in NAFLD/NASH progression. Lab Invest 2015;95:1130–44.
    Article CAS Google Scholar
  37. McMahan RH, Porsche CE, Edwards MG, Rosen HR. Free fatty acids differentially downregulate chemokines in liver sinusoidal endothelial cells: insights into non-alcoholic fatty liver disease. PLoS One 2016;11.
    Article Google Scholar
  38. Tateya S, Rizzo NO, Handa P, Cheng AM, Morgan-Stevenson V, Daum G, et al. Endothelial NO/cGMP/VASP signaling attenuates Kupffer cell activation and hepatic insulin resistance induced by high-fat feeding. Diabetes 2011;60:2792–801.
    Article CAS Google Scholar
  39. May JM, Qu ZC, Xia L, Cobb CE. Nitrite uptake and metabolism and oxidant stress in human erythrocytes. Am J Physiol Cell Physiol 2000;279:C1946–54.
    Article CAS Google Scholar
  40. Konstantynowicz K, Mikłosz A, Stepek T, Chabowski A. The role of hepatic lipid accumulation in the development of insulin resistance in the liver. Postep Hig Med Dosw 2011;65:236–43.
    Article Google Scholar

Download references